- Overnight Policy Shift: EviCore abruptly reclassified low-dose radiation therapy (LDRT) for non-cancer conditions as 'not medically necessary' on November 5, 2026, despite prior coverage.
- Legal Challenge: A coalition of radiation oncologists filed a lawsuit on November 4, 2026, seeking an emergency injunction to block the new guidelines.
- Patient Impact: The policy change threatens access to LDRT for millions of insured Americans, potentially pushing them toward more invasive or addictive treatments.
Experts would likely conclude that this case highlights the growing conflict between corporate cost-cutting measures and evidence-based clinical care, with significant implications for patient access to treatment.
The Prior Authorization Revolt: Doctors Take Benefit Managers to Court
WINTER PARK, Fla. – November 16, 2026 — For years, patients suffering from debilitating chronic pain caused by osteoarthritis or plantar fasciitis had a reliable, non-invasive fallback when conventional treatments failed: low-dose radiation therapy. Then, seemingly overnight, the doors slammed shut.
On November 5, EviCore, one of the nation's largest healthcare benefits managers, abruptly revised its clinical utilization guidelines. The Franklin, Tennessee-based company reclassified low-dose radiation therapy (LDRT) for almost all non-cancer conditions as "not medically necessary," citing a "paucity of evidence."
The sudden reversal has sparked a high-stakes legal confrontation. On November 4, anticipating the policy shift, a coalition of radiation oncologists and medical physicists known as the Radiotherapy Access Alliance filed a lawsuit in Florida's Orange County Circuit Court. Represented by Arnall Golden Gregory, LLP, the group is seeking an emergency injunction to halt the new guidelines and force the benefits manager to evaluate Florida patients under its previous, more permissive rules.
This is not just another squabble over medical billing. It is a frontline skirmish in a growing revolt against third-party utilization management. Because the targeted company dictates treatment approvals for commercial insurance giants like Blue Cross, Aetna, and Cigna, its coverage withdrawal threatens millions of insured Americans and tests whether state courts can hold corporate algorithms accountable for interfering with clinical judgment.
Overnight Denials and the Human Toll
To understand the gravity of this policy shift, one must look past the boardroom and into the clinic. Low-dose radiation therapy uses significantly lower doses of radiation than standard cancer treatments to reduce inflammation, ease pain, and improve mobility. For elderly patients or those with severe comorbidities, it is often the last line of defense before invasive surgery or reliance on highly addictive opioids.
For over a decade, the benefits manager covered LDRT for benign inflammatory conditions. As recently as February 2026, the company's own guidelines acknowledged the treatment as necessary, noting it was "associated with a response rate approaching 80% and durable at 48 weeks."
Then came the November 5 revision, which eliminated coverage for nearly all benign conditions—carving out a bizarre, solitary exception for tennis elbow. Overnight, chronic pain patients found their authorized therapies abruptly canceled.
"Our alliance, our specialty societies and other radiation companies tried to reach out to EviCore to get them not to reverse themselves, but those attempts didn't go anywhere," said Evan Thomas, M.D., Ph.D., a radiation oncologist in Winter Park and president of the newly formed Radiotherapy Access Alliance. "So we decided we had to sue."
Medical professionals on the ground report that the sudden cutoff has left vulnerable patients stranded. Without access to LDRT, individuals with severe osteoarthritis are being pushed toward more expensive, higher-risk joint replacement surgeries or long-term pain management regimens that carry their own devastating side effects.
Science Versus Cost Cutting
The central justification for the coverage denial—a claimed lack of evidence—stands in stark contrast to both international medical standards and the company's own historical data.
In parts of Europe, particularly Germany, LDRT has been standard medical care for decades. The German national radiotherapy guideline (DEGRO) explicitly recommends the treatment for benign inflammatory diseases, and the UK Royal College of Radiologists has given it a Grade A recommendation for plantar fasciitis. In the United States, Medicare and most major commercial plans have generally covered the therapy when medically appropriate, supported by clinical trials demonstrating response rates for pain reduction between 65 and 77 percent.
Industry analysts and health economists suggest the sudden reversal has less to do with scientific skepticism and more to do with aggressive cost containment. Utilization management companies are increasingly applying stringent prior authorization rules to specialized therapeutic areas like oncology. The goal is often to curb health spending, but critics argue these contracts can incentivize blanket denials over nuanced clinical care.
A former medical director familiar with utilization review processes noted that algorithmic determinations, sometimes referred to internally as "the dial," are frequently calibrated to target high-volume procedures. By reclassifying a widely used, effective treatment as experimental or unnecessary, benefits managers can instantly wipe millions of dollars in potential claims from the ledgers of their insurer clients.
A Novel Legal Strategy
What makes the Radiotherapy Access Alliance's lawsuit uniquely compelling is its legal architecture. Rather than pursuing a protracted federal antitrust case or seeking massive financial damages, the coalition is utilizing state tort law.
The suit alleges that the benefits manager has unlawfully interfered with the fundamental relationship between doctors and their patients under Florida law. By seeking purely declaratory relief—asking the judge to rule on the parties' rights and block the November 5 guidelines—the plaintiffs are aiming to establish a legal precedent against arbitrary care denials.
If successful, this strategy could provide a blueprint for other medical specialties suffocating under prior authorization mandates. Establishing that a third-party benefits manager can be held liable in state court for tortious interference would fundamentally alter the balance of power in American healthcare, stripping these corporate entities of the impunity they have long enjoyed when overruling treating physicians.
The Broader War on Prior Authorization
This Florida lawsuit does not exist in a vacuum; it is a flashpoint in a nationwide backlash against the prior authorization industrial complex.
Physicians are exhausted. Surveys consistently show that administrative tasks tied to prior authorization consume over 12 hours per week for the average clinician, costing the U.S. healthcare system an estimated $20 billion annually. More alarmingly, 79 percent of physicians report that these administrative hurdles lead to patients abandoning recommended treatments entirely.
Regulators are finally taking notice. The Centers for Medicare and Medicaid Services (CMS) recently finalized the Interoperability and Prior Authorization Rule, which took effect in January 2026. The rule mandates that payers make decisions within 72 hours for urgent requests and requires specific, documented reasons for denials. Furthermore, several states are experimenting with "gold carding" programs that exempt providers with high approval rates from prior authorization requirements.
Even the corporate giants are feeling the heat. In May 2026, The Cigna Group—which owns EviCore through its Evernorth subsidiary—announced it was exploring "strategic alternatives" for the benefits manager, signaling potential divestitures or partnerships as the regulatory environment grows increasingly hostile to traditional utilization management models.
As the Radiotherapy Access Alliance awaits a ruling on its emergency injunction, the healthcare industry is watching closely. The outcome in Orange County Circuit Court will not just determine whether a Florida grandmother can get radiation therapy for her aching knees. It will test whether the legal system can finally draw a hard line between legitimate medical oversight and the automated, profit-driven denial of human care.
Topics & Related
📝 This article is still being updated
Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.
Contribute Your Expertise →